Kalender Press & nyheter Investor relations Jobb Läkemedel Biopharmaceuticals Partnerskap FoU Om oss Calendar Press and news Investor relations Jobs Products Biopharmaceuticals Partnering R&D About us Sök Kontakt .com Hem Ordlista .se home contact glossary search


contact.
Image of Erik Kinnman

Erik Kinnman
Executive Vice President, Chief Strategic Officer and Head of Investor Relations & Public Affairs
 
E-mail

+46 8 697 20 00




Our Specialist Pharma Strategy paves the way for future growth and enables a strong international presence

Biovitrum is an international pharmaceutical company that markets specialist pharmaceuticals in several regions globally.
 

Using its expertise and experience Biovitrum takes scientific innovation to patients with significant unmet medical need. Research expertise and capabilities are focused on development and production of biotechnology therapeutics within our prioritized areas of hemophilia, inflammation/autoimmune diseases, cancer supportive care and malabsorption.
 

The company has revenues of approximately SEK 1.2 billion and around 400 employees. The company head office is located in Sweden and it is listed on the Stockholm OMX Nordic Exchange.

 
Sales and Marketing
Biovitrum is currently promoting proprietary products internationally, i.e. in Europe, North America, Australia and New Zealand, and a portfolio of prescription specialist products in the Nordic countries in collaboration with Pfizer, Amgen and other selected pharmaceutical and biotechnology companies.

 

Going forward, we intend to commercialize additional partnered products as well as products developed from our own project portfolio.

 
Research and development
We develop protein pharmaceuticals for specialist care all the way to launching, marketing and sales through our own organization.

 

Our operations are based on extensive experience in research and pharmaceutical development. Several of Biovitrum’s scientists were pioneers in biotechnology and protein drug process development.

 

We have in-house research operations including cutting-edge expertise in the fields of hematology, autoimmune diseases/inflammation and malabsorption related to specialist care. The influx of new projects from our own research is complemented by strategic acquisitions, partnerships and alliances. Our project portfolio includes several projects in late clinical phases.

 
Partnering
We are looking for collaboration opportunities in specialist pharmaceuticals.
 

We are looking for drugs in specialist care for in-licensing. We offer comprehensive expertise from contact with authorities, clinical trials, brand development and medical marketing.

 
Protein Pharmaceuticals
Biopharmaceuticals have profound expertise in protein therapeutic development, from cell line development through formulation design to manufacturing for preclinical, clinical and commercial supply. Our operations are based on strong commitment, scientific credibility and exceptional regulatory experience (e.g. EMEA, FDA). Our current partners are active in Europe and the US. Biovitrum is the sole global manufacturer of the active substance in Pfizer's ReFacto AF®, a protein used for treatment of hemophilia.

 

New mindsets and commitment
We encourage an environment where good ideas and engagement are rewarded and have built an organization where decision-making paths are short. Our success is based on the dynamics of this culture and the partnerships we establish.
 

We are always open to discussions on innovative ideas and are keen to establish alliances with others to develop new pharmaceuticals that can give people a better life and thus generate lasting value.







Martin Nicklasson
Picture of Martin Nicklasson

CEO comments from the latest Interim Report:
“The third quarter showed both a gratifying sales development for our marketed products and a continued good progress of our prioritized R&D projects. In particular, the sales of Kineret® and Kepivance® in local currency were the highest since Biovitrum acquired the products. The financial performance for the quarter as well as for the nine month period is yet another step forward becoming a profitable company. I am particularly pleased that we after the period have decided to move the hemophilia B project (rFIXFc) into the final registrational development phase, based on successful outcome of a phase I/II clinical trial. Furthermore the sale of our UK research company is also highly satisfying and in line with the transformation of our business. In order to drive future growth, we continue to strengthen our commercial infrastructure needed for our key products”

 

Martin Nicklasson, Chief Executive Officer


Facts

Biovitrum is an international pharmaceutical company that markets specialist pharmaceuticals in several regions globally.

 
Using its expertise and experience Biovitrum takes scientific innovation to patients with significant unmet medical need. Research expertise and capabilities are focused on development and production of biotechnology therapeutics within our prioritized areas of hemophilia, inflammation/autoimmune diseases, cancer supportive care and malabsorption.